| 1 |
NCT00101140 |
Withdrawn |
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission |
- Adult Acute Erythroid Leukemia
- Adult Acute Monoblastic and Acute Monocytic Leukemia
- Adult Acute Myeloid Leukemia
|
- Drug: anti-thymocyte globulin
- Drug: fludarabine phosphate
- Drug: thiotepa
- (and 6 more...)
|
Interventional
|
Phase 2 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
0 |
All |
18 Years to 59 Years (Adult) |
NCT00101140 |
CDR0000405838
ECOG-E1903 |
|
|
|
|
January 10, 2005 |
October 19, 2017 |
|
|
|
| 2 |
NCT01642121 |
Completed |
Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia |
- Childhood Acute Monoblastic Leukemia (M5a)
- Childhood Acute Monocytic Leukemia (M5b)
- Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
- (and 2 more...)
|
- Other: laboratory biomarker analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Expression of the CD55 marker on CD34+CD38‐ cells
- Presence of the AML1-ETO translocation
|
20 |
All |
up to 30 Years (Child, Adult) |
NCT01642121 |
AAML12B10
NCI-2012-01983 |
|
August 2012 |
May 2016 |
|
July 17, 2012 |
May 19, 2016 |
|
- Children's Oncology Group
Monrovia, California, United States
|
|
| 3 |
NCT01801046 |
Terminated |
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 24 more...)
|
- Drug: mitoxantrone hydrochloride
- Drug: cytarabine
- Procedure: peripheral blood stem cell transplantation
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- University of Southern California
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Induction mortality
- Complete remission rate (complete remission [CR] or incomplete remission [CRi])
- Occurrence of serious infections (grade 4) assessed using National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) v4.0
- (and 5 more...)
|
10 |
All |
Child, Adult, Older Adult |
NCT01801046 |
9L-11-8
NCI-2013-00447 |
|
March 6, 2013 |
July 27, 2017 |
August 20, 2017 |
February 28, 2013 |
March 30, 2018 |
|
- USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
|
|
| 4 |
NCT01307579 |
Active, not recruiting |
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 28 more...)
|
- Drug: caspofungin acetate
- Drug: fluconazole
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Time to development of proven or probable IFI, defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
- Time to development of proven or probably invasive aspergillosis (IA), defined according to the criteria developed by the EORTC/MSG
- Time to death due to any cause
- Total days of empiric antifungal therapy while a patient is receiving prophylaxis
|
517 |
All |
3 Months to 30 Years (Child, Adult) |
NCT01307579 |
ACCL0933
NCI-2011-02640
CDR0000695748
COG-ACCL0933
U10CA095861 |
|
April 2011 |
June 2018 |
|
March 3, 2011 |
November 17, 2017 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 156 more...)
|
|
| 5 |
NCT00666588 |
Completed
Has Results |
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia |
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- Adult Acute Myeloblastic Leukemia With Maturation (M2)
- (and 19 more...)
|
- Drug: idarubicin
- Drug: cytarabine
- Drug: bortezomib
- (and 2 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity
- Overall Response (Complete Remission [CR] and CR With Partial Recovery [CRp]) During Course 1
- NF-kB Activity by Enzyme-linked Immunosorbent Assay (ELISA)
- (and 3 more...)
|
52 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00666588 |
NCI-2009-00323
U10CA098543
CDR0000594224
COG-AAML07P1 |
|
April 2008 |
December 2012 |
December 2012 |
April 25, 2008 |
May 22, 2018 |
February 6, 2014 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 79 more...)
|
|
| 6 |
NCT00096148 |
Terminated |
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 21 more...)
|
- Drug: idarubicin
- Drug: cytarabine
- Biological: bevacizumab
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients who remain alive in the first complete remission (CR) 1 year from achievement of CR assessed every 3 weeks for 1 year
- Safety of idarubicin+cytarabine+bevacizumab by AdEERS, CBC and chem.
|
120 |
All |
up to 59 Years (Child, Adult) |
NCT00096148 |
NCI-2012-02627
MDA-2004-0342
N01CM62202
N01CM62204
CDR0000391189 |
|
October 2004 |
November 2006 |
|
November 9, 2004 |
January 24, 2013 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 7 |
NCT00462605 |
Completed
Has Results |
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia |
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 25 more...)
|
- Drug: entinostat
- Drug: sargramostim
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response (Complete and Partial Response) in Patients With Myeloid Disorders
- Clinical Activity Assessed by Change in Peripheral Blood Counts
- Clinical Activity Assessed by Change in Transfusion Requirements
- (and 2 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT00462605 |
NCI-2009-00195
J06114
U01CA070095 |
|
April 2007 |
March 2011 |
March 2011 |
April 19, 2007 |
July 18, 2017 |
April 17, 2017 |
- Johns Hopkins University
Baltimore, Maryland, United States
|
|
| 8 |
NCT00101296 |
Completed |
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Erythroid Leukemia (M6)
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 16 more...)
|
- Drug: tipifarnib
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD defined as the highest dose level in which six patients have been evaluated for toxicity with no more than one patient experiencing dose limiting toxicity (DLT) assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
- Objective tumor response
- Survival
- (and 2 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT00101296 |
NCI-2012-03078
PHI-47
U01CA062505
CDR0000404151 |
|
October 2004 |
May 2011 |
|
January 10, 2005 |
February 4, 2013 |
|
- City of Hope
Duarte, California, United States
|
|
| 9 |
NCT00027872 |
Completed |
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- (and 18 more...)
|
- Drug: tipifarnib
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete remission (CR) rate
- Partial remission (PR) rate
- Toxicity rates assessed using NCI CTCAE version 3.0
- (and 2 more...)
|
125 |
All |
65 Years and older (Older Adult) |
NCT00027872 |
NCI-2012-02980
UMGCC 0116
U01CA069854
U01CA070095 |
|
October 2001 |
July 2007 |
January 2009 |
January 27, 2003 |
March 25, 2013 |
|
- Johns Hopkins University
Baltimore, Maryland, United States
|
|
| 10 |
NCT02038153 |
Unknown † |
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant |
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monoblastic Leukemia
- (and 14 more...)
|
- Drug: Lenalidomide
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 1
Phase 2 |
- Albert Einstein College of Medicine, Inc.
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse free survival rate
- Overall survival
|
48 |
All |
60 Years to 75 Years (Adult, Older Adult) |
NCT02038153 |
13-08-148
NCI-2013-02493
P30CA013330 |
|
December 2013 |
January 2016 |
January 2017 |
January 16, 2014 |
March 3, 2015 |
|
- Albert Einstein College of Medicine
Bronx, New York, United States - Montefiore Medical Center - Moses Campus
Bronx, New York, United States
|
|
| 11 |
NCT00658814 |
Active, not recruiting
Has Results |
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
- Acute Myeloid Leukemia
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monoblastic Leukemia
- (and 12 more...)
|
- Drug: Azacitidine
- Drug: Gemtuzumab Ozogamicin
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response
- 30-Day Survival
- Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
- Relapse-free Survival
|
133 |
All |
60 Years and older (Adult, Older Adult) |
NCT00658814 |
NCI-2009-00790
CDR0000593117
SWOG-S0703
S0703
U10CA032102 |
|
December 1, 2008 |
June 1, 2013 |
|
April 15, 2008 |
April 24, 2018 |
January 6, 2014 |
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States - Stanford Cancer Institute Palo Alto
Palo Alto, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - (and 175 more...)
|
|
| 12 |
NCT01260714 |
Terminated |
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia |
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- (and 18 more...)
|
- Drug: Azacitidine
- Drug: Etoposide
- Other: Laboratory Biomarker Analysis
- Drug: Mitoxantrone Hydrochloride
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose of azacitidine that can be safely combined with mitoxantrone hydrochloride and etoposide chemotherapy
- Changes in DNA methylation
- Changes in gene expression
- (and 4 more...)
|
13 |
All |
60 Years and older (Adult, Older Adult) |
NCT01260714 |
NCI-2011-02559
CDR0000690647
PHL-074
8331
N01CM00032
N01CM62203 |
|
December 2010 |
March 2015 |
June 2015 |
December 15, 2010 |
August 20, 2015 |
|
- Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada - University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
|
|
| 13 |
NCT01627041 |
Active, not recruiting |
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia |
- Acute Myeloid Leukemia
- Adult Acute Basophilic Leukemia
- Adult Acute Monoblastic Leukemia
- (and 8 more...)
|
- Drug: Cytarabine
- Drug: Daunorubicin Hydrochloride
- Drug: Decitabine
- (and 2 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete remission rate (CR1)
- Complete remission rate (CR1 + CR2)
- Overall survival
- (and 4 more...)
|
180 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01627041 |
NCI-2012-01959
1106011736
CDR0000712322
8854
N01CM62204
P30CA013696 |
|
September 16, 2011 |
October 1, 2022 |
|
June 25, 2012 |
May 25, 2018 |
|
- Lafayette Family Cancer Center-EMMC
Brewer, Maine, United States - Montefiore Medical Center-Weiler Hospital
Bronx, New York, United States - Montefiore Medical Center - Moses Campus
Bronx, New York, United States - (and 6 more...)
|
|
| 14 |
NCT00742625 |
Completed
Has Results |
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
- Acute Myeloid Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 12 more...)
|
- Drug: daunorubicin hydrochloride
- Drug: cytarabine
- Drug: bortezomib
|
Interventional
|
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Remission Induction Response
- Participants Experiencing a Dose-limiting Toxicity (DLT) of Bortezomib When Administered in Combination With Intermediate-dose Cytarabine
- Disease-free Survival
- Overall Survival
|
95 |
All |
60 Years to 75 Years (Adult, Older Adult) |
NCT00742625 |
NCI-2009-00443
CDR0000612758
CALGB 10502
CALGB-10502
U10CA031946
P30CA014236 |
|
September 2008 |
July 2010 |
December 2012 |
August 28, 2008 |
September 12, 2014 |
February 5, 2013 |
- Washington Hospital Center
Washington, District of Columbia, United States - Lombardi Comprehensive Cancer Center at Georgetown University
Washington, District of Columbia, United States - Florida Hospital
Orlando, Florida, United States - (and 19 more...)
|
|
| 15 |
NCT01349972 |
Completed
Has Results |
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 13 more...)
|
- Drug: alvocidib
- Drug: daunorubicin hydrochloride
- Drug: mitoxantrone hydrochloride
- Drug: cytarabine
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Rate
- Incidence of Toxicities, Characterized by Number of Events by Treatment and Grade
- Disease-free Survival
- (and 3 more...)
|
172 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01349972 |
NCI-2011-02587
JHOC-J1101
CDR0000699421
J1101
8972
U01CA070095
N01CM00100
P30CA006973 |
|
April 2011 |
May 2014 |
May 2014 |
May 9, 2011 |
July 31, 2017 |
June 6, 2017 |
- Mayo Clinic Scottsdale-Phoenix
Scottsdale, Arizona, United States - Moffitt Cancer Center
Tampa, Florida, United States - Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States - (and 8 more...)
|
|
| 16 |
NCT01521936 |
Terminated |
Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 11 more...)
|
- Dietary Supplement: cholecalciferol
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Changes in 25(OH)-D3 levels after supplementation
- Pharmacokinetic parameters
- Safety and toxicity parameters
|
4 |
All |
18 Years and older (Adult, Older Adult) |
NCT01521936 |
I 201311
NCI-2011-03554 |
|
December 2011 |
March 2013 |
June 2015 |
January 31, 2012 |
June 19, 2015 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 17 |
NCT01904643 |
Terminated |
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: lenalidomide
- Drug: mitoxantrone hydrochloride
- Drug: etoposide
- Drug: cytarabine
|
Interventional
|
Phase 1 |
- Stanford University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of lenalidomide when used in combination with MEC determined by DLT using the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
- Response rate (complete remission [CR], CR with incomplete blood count recovery [CRi], partial remission [PR] or stable disease [SD]) using LeukemiaNet guidelines
- Response duration
- Early mortality
|
17 |
All |
18 Years and older (Adult, Older Adult) |
NCT01904643 |
HEMAML0024
NCI-2013-01349
27313
P30CA124435 |
|
February 2014 |
May 13, 2015 |
July 18, 2015 |
July 22, 2013 |
May 28, 2018 |
|
- Stanford University, School of Medicine
Stanford, California, United States
|
|
| 18 |
NCT00634244 |
Completed
Has Results |
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 11 more...)
|
- Drug: alvocidib
- Drug: mitoxantrone hydrochloride
- Drug: carboplatin
- (and 4 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Rate of Complete Remission (CR+CRi)
- The Rate of Treatment Failure
|
92 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00634244 |
NCI-2009-00520
E1906
U10CA021115 |
|
October 2008 |
September 2014 |
October 2014 |
March 12, 2008 |
July 7, 2015 |
July 7, 2015 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - (and 17 more...)
|
|
| 19 |
NCT02030405 |
Terminated
Has Results |
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
|
Interventional
|
Phase 2 |
- Bruno C. Medeiros
- National Cancer Institute (NCI)
- Stanford University
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Overall Survival (OS)
|
4 |
All |
18 Years and older (Adult, Older Adult) |
NCT02030405 |
IRB-28771
NCI-2013-02231
P30CA124435
HEMAML0028 |
|
March 2014 |
November 2015 |
November 2015 |
January 8, 2014 |
March 10, 2017 |
March 10, 2017 |
- Stanford University Cancer Institute
Stanford, California, United States
|
|
| 20 |
NCT01820624 |
Completed |
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 11 more...)
|
- Drug: tretinoin
- Drug: lithium carbonate
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- Paolo Caimi, MD
- National Cancer Institute (NCI)
- Case Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of tretinoin when given together with lithium carbonate, defined as the dose level immediately below that at which at least 2/6 subjects experience dose-limiting toxicity (DLT), graded using the NCI CTCAE version 4.0
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT01820624 |
CASE3912
NCI-2013-00600 |
|
April 30, 2013 |
October 9, 2015 |
November 13, 2015 |
March 29, 2013 |
April 27, 2017 |
|
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 21 |
NCT02049801 |
Terminated |
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 12 more...)
|
- Drug: MEK inhibitor MEK162
- Drug: idarubicin
- Drug: cytarabine
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Bruno C. Medeiros
- National Cancer Institute (NCI)
- Stanford University
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of MEK inhibitor MEK162 in combination with chemotherapy, defined as the dose associated with a dose-limiting toxicity rate of 35% assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
- Pharmacodynamic analysis of downstream inhibition of RAS signaling following therapy with single-agent MEK inhibitor MEK162
- Complete remission rate, defined as bone marrow biopsy demonstrating < 5% blasts and recovery of peripheral blood counts after induction chemotherapy
- (and 2 more...)
|
1 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02049801 |
IRB-29150
NCI-2014-00169
HEMAML0030 |
|
December 2014 |
February 4, 2015 |
November 1, 2017 |
January 30, 2014 |
December 6, 2017 |
|
- Stanford University, School of Medicine
Stanford, California, United States
|
|
| 22 |
NCT01835288 |
Withdrawn |
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: arsenic trioxide
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Stanford University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of complete remission following arsenic trioxide induction
- Median duration of remission
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT01835288 |
IRB-26938
NCI-2013-00767
HEMAML0023 |
|
May 2013 |
May 2015 |
|
April 18, 2013 |
May 21, 2018 |
|
|
|
| 23 |
NCT01831232 |
Completed
Has Results |
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 16 more...)
|
- Drug: pravastatin sodium
- Drug: idarubicin
- Drug: cytarabine
- Other: laboratory biomarker analysis
|
Interventional
|
Not Applicable |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Good Complete Remission (CR)
- Number of Participants With TRM.
- Progression Free Survival (PFS)
- (and 3 more...)
|
24 |
All |
18 Years to 74 Years (Adult, Older Adult) |
NCT01831232 |
2674.00
NCI-2013-00743
P30CA015704 |
|
May 2013 |
February 2015 |
January 2016 |
April 15, 2013 |
November 17, 2017 |
November 17, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 24 |
NCT02029417 |
Terminated
Has Results |
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 14 more...)
|
- Drug: cytarabine
- Drug: omacetaxine mepesuccinate
- Drug: decitabine
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
- Teva Pharmaceutical Industries, Ltd.
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of the Evaluable Population of Interest Who Experience a Complete Response in the Poor and Good Prognosis Groups
- Frequency of Adverse Events, Graded According to NCI CTCAE v4.0
|
2 |
All |
65 Years and older (Older Adult) |
NCT02029417 |
I 245213
NCI-2013-02425
P30CA016056 |
|
July 2014 |
November 2015 |
December 2015 |
January 7, 2014 |
May 9, 2016 |
May 9, 2016 |
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 25 |
NCT02085408 |
Active, not recruiting |
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 14 more...)
|
- Drug: clofarabine
- Drug: daunorubicin hydrochloride
- Other: clinical observation
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Mortality rate
- Induction complete response rates
- (and 4 more...)
|
727 |
All |
60 Years and older (Adult, Older Adult) |
NCT02085408 |
E2906
NCI-2011-01992
CDR0000659585
ECOG-E2906
U10CA021115 |
|
December 28, 2010 |
September 2018 |
|
March 12, 2014 |
December 8, 2017 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Arizona Cancer Center at University Medical Center North
Tucson, Arizona, United States - (and 266 more...)
|
|
| 26 |
NCT01555268 |
Completed |
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 13 more...)
|
- Biological: trebananib
- Drug: cytarabine
- Other: laboratory biomarker analysis
- Other: pharmacological study
|
Interventional
|
Phase 1 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
- Amgen
|
Other / NIH / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of trebananib when administered alone and in combination with low-dose cytarabine measured by number of participants with toxicities according to CTCAE
- PK/PD profile of trebananib when administered alone
- PK/PD profile of trebananib when administered in combination with low-dose cytarabine
- (and 5 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT01555268 |
I 186010
NCI-2011-02979
P30CA016056 |
|
October 31, 2011 |
September 24, 2013 |
August 3, 2016 |
March 15, 2012 |
February 15, 2017 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States - University of Rochester
Rochester, New York, United States
|
|
| 27 |
NCT01550185 |
Terminated |
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 14 more...)
|
- Drug: eltrombopag olamine
- Procedure: standard follow-up care
|
Interventional
|
Phase 1 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
- GlaxoSmithKline
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD and tolerability of eltrombopag olamine in patients with AML, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4
- Platelet count recovery to >= 100 x 10^9/L when eltrombopag olamine is administered following high dose cytarabine and mitoxantrone for the treatment of AML patients
- Platelet recovery to >= 100 x 10^9/L and platelet response, assessed based on a modified International Working Group Consensus Criteria for hematologic improvement
- (and 2 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT01550185 |
I 206111
NCI-2012-00215 |
|
May 2012 |
December 2014 |
December 2014 |
March 9, 2012 |
April 6, 2016 |
|
- Emory University, Winship Cancer Institute
Atlanta, Georgia, United States - Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 28 |
NCT00407966 |
Completed
Has Results |
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 14 more...)
|
- Drug: alvocidib
- Drug: cytarabine
- Drug: mitoxantrone hydrochloride
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT00407966 |
NCI-2012-02986
U01CA070095
P30CA006973
J0669
7845 |
|
October 2006 |
July 2008 |
November 2009 |
December 5, 2006 |
August 4, 2015 |
February 11, 2013 |
- Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
|
|
| 29 |
NCT01342887 |
Terminated
Has Results |
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: cyclosporine
- Drug: pravastatin sodium
- Drug: mitoxantrone hydrochloride
- (and 2 more...)
|
Interventional
|
Phase 1
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Doses Mitoxantrone Hydrochloride and Etoposide When Combined With Cyclosporine and Pravastatin Sodium
- CR/CRi
- Disease-free Survival of Patients That Achieve CR/CRi
- Frequency and Severity of Regimen-associated Toxicities
|
6 |
All |
18 Years and older (Adult, Older Adult) |
NCT01342887 |
2409.00
NCI-2011-00657 |
|
April 2011 |
March 2012 |
March 2012 |
April 27, 2011 |
July 2, 2017 |
July 2, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 30 |
NCT02071901 |
Recruiting |
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- (and 16 more...)
|
- Drug: eltrombopag olamine
|
Interventional
|
Phase 2 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Patients with a median platelet count >= 50,000/uL
- Median time needed to reach platelet count >= 50,000 /µL
- Number of days of platelet transfusions
- (and 10 more...)
|
31 |
All |
60 Years and older (Adult, Older Adult) |
NCT02071901 |
CASE4913
NCI-2014-00252
P30CA043703 |
|
August 14, 2014 |
October 2018 |
October 2018 |
February 26, 2014 |
April 18, 2018 |
|
- Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 31 |
NCT00093418 |
Completed |
S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 14 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Total response rate, defined as the proportion of patients who achieve CR or PR
|
296 |
All |
70 Years and older (Older Adult) |
NCT00093418 |
NCI-2012-03038
S0432
U10CA032102
CDR0000387957 |
|
September 2004 |
June 2006 |
|
October 8, 2004 |
January 15, 2013 |
|
- Southwest Oncology Group
San Antonio, Texas, United States
|
|
| 32 |
NCT00305773 |
Completed
Has Results |
Vorinostat in Treating Patients With Acute Myeloid Leukemia |
- Adult Acute Erythroid Leukemia (M6)
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 15 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Confirmed Complete Response (CR) Rate
- Time to Progression (TTP)
- Overall Survival (OS)
- Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events
|
37 |
All |
18 Years and older (Adult, Older Adult) |
NCT00305773 |
NCI-2012-01470
CDR0000465213
JHOC-J0557
MAYO-MC0483
JHOC-J0550
NCI-6882
MC0483
6882
N01CM62205
P30CA015083 |
|
January 2006 |
May 2009 |
January 2010 |
March 22, 2006 |
May 19, 2014 |
May 16, 2013 |
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 33 |
NCT00673153 |
Terminated
Has Results |
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: gemtuzumab ozogamicin
- Drug: vorinostat
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Achieving CR or CRi With Induction Therapy (Good-risk Group)
- Number of Participants Alive at Day 30 (Poor-risk Group)
- Relapse-free Survival (Good- and Poor-risk Group)
- (and 2 more...)
|
31 |
All |
60 Years and older (Adult, Older Adult) |
NCT00673153 |
2200.00
NCI-2010-00401 |
|
March 2008 |
August 2010 |
|
May 7, 2008 |
June 1, 2017 |
June 1, 2017 |
- Stanford University
Stanford, California, United States - Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States - Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States - Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 34 |
NCT02144675 |
Completed |
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 14 more...)
|
- Drug: choline magnesium trisalicylate
- Drug: idarubicin
- Drug: cytarabine
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- Rutgers, The State University of New Jersey
- Rutgers Cancer Institute of New Jersey
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Inhibition of NF-kB target transcripts and/or inhibition of drug efflux in at least 50% of patients
|
27 |
All |
18 Years and older (Adult, Older Adult) |
NCT02144675 |
020803
NCI-2012-00516
0220080282
P30CA072720 |
|
January 2009 |
April 26, 2016 |
April 26, 2016 |
May 22, 2014 |
February 2, 2017 |
|
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
|
|
| 35 |
NCT00352365 |
Completed
Has Results |
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 14 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response
- Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
- Cytogenetic Abnormalities
- Total Response
|
41 |
All |
60 Years and older (Adult, Older Adult) |
NCT00352365 |
NCI-2009-00785
SWOG-S0605
CDR0000484449
S0605
U10CA032102 |
|
June 2006 |
December 2010 |
July 2011 |
July 14, 2006 |
July 31, 2014 |
July 4, 2013 |
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Shasta Regional Medical Center
Redding, California, United States - Sutter Roseville Medical Center
Roseville, California, United States - (and 51 more...)
|
|
| 36 |
NCT00089388 |
Terminated |
Cilengitide in Treating Patients With Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 9 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival (DFS)
- Overall survival
- Toxicity of cilengitide graded using the CTC version 3
|
70 |
All |
50 Years and older (Adult, Older Adult) |
NCT00089388 |
NCI-2012-02621
MDA-2003-1007
CDR0000378310 |
|
July 2004 |
June 2006 |
|
August 5, 2004 |
January 24, 2013 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 37 |
NCT01361464 |
Completed
Has Results |
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monoblastic Leukemia
- Adult Acute Monocytic Leukemia
- (and 13 more...)
|
- Drug: Tipifarnib
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Remission (CR) Rate
- Median Overall Survival (OS)
- Median 1-Year Survival Rate
- Number of Participants With Relapse Free Survival
|
21 |
All |
65 Years and older (Older Adult) |
NCT01361464 |
NCI-2011-02589
16572
CDR0000699713
8977
P30CA076292
N01CM00071
U01CA070095
N01CM00100 |
|
May 2011 |
November 2014 |
November 2014 |
May 26, 2011 |
April 8, 2015 |
January 6, 2014 |
- Moffitt Cancer Center
Tampa, Florida, United States - Emory University/Winship Cancer Institute
Atlanta, Georgia, United States - Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States - (and 4 more...)
|
|
| 38 |
NCT01839240 |
Active, not recruiting |
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 14 more...)
|
- Drug: azacitidine
- Drug: cytarabine
- Drug: mitoxantrone hydrochloride
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- University of Chicago
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase II dose of azacitidine when combined with high-dose cytarabine and mitoxantrone hydrochloride, based on incidence of dose limiting toxicity (DLT) graded according to the National Cancer Institute Common Toxicity Criteria, version 4
- Change in gene expression levels of topoisomerase II and deoxycytidine kinase in leukemic blasts pre-treatment and following therapy with azacitidine will be measured by real-time polymerase chain reaction (RT-PCR)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT01839240 |
12-0111
NCI-2012-02028 |
|
June 6, 2012 |
September 2018 |
September 2018 |
April 24, 2013 |
January 4, 2018 |
|
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
|
|
| 39 |
NCT01822015 |
Active, not recruiting |
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- (and 11 more...)
|
- Drug: Sirolimus
- Drug: Idarubicin
- Drug: Cytarabine
|
Interventional
|
Early Phase 1 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in measurement of mTOR activation paired with mTOR target inhibition
- Overall survival
- Progression free survival
- (and 2 more...)
|
55 |
All |
18 Years and older (Adult, Older Adult) |
NCT01822015 |
12D.588
2012-55 |
|
March 15, 2013 |
December 2019 |
June 2020 |
April 1, 2013 |
April 24, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 40 |
NCT00217646 |
Completed |
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia
- (and 21 more...)
|
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT00217646 |
NCI-2009-00081
CDR0000442847
2004-0702
6742
P30CA016672
U01CA062461 |
|
October 2005 |
December 2010 |
|
September 22, 2005 |
April 28, 2015 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 41 |
NCT00369317 |
Completed
Has Results |
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes |
- Childhood Acute Basophilic Leukemia
- Childhood Acute Eosinophilic Leukemia
- Childhood Acute Erythroleukemia (M6)
- (and 12 more...)
|
- Drug: asparaginase
- Drug: daunorubicin hydrochloride
- Drug: cytarabine
- (and 3 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free Survival (EFS) at 3 Years
- Overall Survival (OS) at 3 Years
- Induction Remission Rate
- (and 6 more...)
|
205 |
All |
up to 4 Years (Child) |
NCT00369317 |
AAML0431
NCI-2009-00318
CDR0000492776
COG-AAML0431
U10CA098543 |
|
March 2007 |
December 2013 |
December 2013 |
August 29, 2006 |
August 14, 2017 |
January 13, 2015 |
- Phoenix Childrens Hospital
Phoenix, Arizona, United States - Southern California Permanente Medical Group
Downey, California, United States - Miller Children's Hospital
Long Beach, California, United States - (and 94 more...)
|
|
| 42 |
NCT01253447 |
Completed
Has Results |
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: Akt inhibitor MK2206
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With a Response of CR, CRp, or PR
- Treatment-related Non-hematological Toxicity
- Maximum Percentage Change in Apoptosis
|
19 |
All |
18 Years and older (Adult, Older Adult) |
NCT01253447 |
NCI-2010-02186
2010-0243
8731
N01CM00039 |
|
October 2010 |
October 2013 |
April 2014 |
December 3, 2010 |
January 7, 2015 |
January 7, 2015 |
- UT MD Anderson Cancer Center
Houston, Texas, United States - Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 43 |
NCT00045435 |
Active, not recruiting
Has Results |
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 14 more...)
|
- Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Drug: fludarabine phosphate
- Radiation: total-body irradiation
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free Survival-incidence of Survival Without Relapse
- Nonrelapse Mortality (NRM)-Incidence of Nonrelapse Death
- Overall Survival
- (and 3 more...)
|
17 |
All |
55 Years and older (Adult, Older Adult) |
NCT00045435 |
1654.00
NCI-2011-01307 |
|
April 2002 |
June 2009 |
|
January 27, 2003 |
June 20, 2018 |
March 16, 2017 |
- OHSU Cancer Institute
Portland, Oregon, United States - Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 44 |
NCT00096122 |
Completed
Has Results |
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia |
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 20 more...)
|
- Drug: cytarabine
- Drug: idarubicin
- Drug: tipifarnib
|
Interventional
|
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Complete Response
|
95 |
All |
15 Years to 70 Years (Child, Adult, Older Adult) |
NCT00096122 |
NCI-2012-02862
2003-0563
6625
N01CM62202 |
|
September 2004 |
September 2006 |
February 2010 |
November 9, 2004 |
May 26, 2014 |
July 15, 2011 |
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 45 |
NCT00098423 |
Completed |
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- (and 23 more...)
|
- Drug: tanespimycin
- Drug: cytarabine
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability of tanespimycin with cytarabine in patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, or high-grade myelodysplastic syndromes
- Clinical response
- Plasma level of tanespimycin
- Effects on client proteins
|
42 |
All |
18 Years and older (Adult, Older Adult) |
NCT00098423 |
NCI-2009-00056
NCI-6383
CDR0000401509
MC0313
6383
U01CA070095
U01CA069912 |
|
November 2004 |
May 2009 |
|
December 8, 2004 |
September 30, 2013 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 46 |
NCT00795002 |
Completed
Has Results |
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 14 more...)
|
- Drug: alvocidib
- Drug: mitoxantrone hydrochloride
- Drug: cytarabine
- (and 2 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response
- Toxicity
- Disease-free Survival
|
78 |
All |
18 Years and older (Adult, Older Adult) |
NCT00795002 |
NCI-2009-00298
CDR0000625222
J0856
8237
P30CA006973
U01CA070095 |
|
November 2008 |
November 2010 |
September 2012 |
November 21, 2008 |
June 30, 2015 |
December 5, 2013 |
- Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 47 |
NCT01127009 |
Completed |
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: bortezomib
- Drug: mitoxantrone hydrochloride
- Drug: etoposide
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Case Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of bortezomib
- Non-dose limiting toxicities
- CR/ CRp rate
- CD74 antigen expression
|
3 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01127009 |
CASE4909
NCI-2010-01203 |
|
July 2010 |
May 2014 |
May 2014 |
May 20, 2010 |
August 13, 2015 |
|
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 48 |
NCT00112853 |
Completed |
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- (and 12 more...)
|
- Drug: tipifarnib
- Drug: etoposide
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients who experience dose limiting toxicities (DLT), based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
- Clinical response in terms of optimal dose combination for further study
- Clinical tolerance in terms of additive or synergistic non-hematologic toxicities grade 2 or greater
- Surrogates of response in terms of cell cycle progression and apoptosis, deoxyribonucleic acid (DNA) damage, and results of in vitro model studies (using pre-post assessments).
|
100 |
All |
70 Years and older (Older Adult) |
NCT00112853 |
NCI-2012-03160
J04110
N01CM62204
U01CA070095 |
|
March 2005 |
May 2009 |
|
June 3, 2005 |
January 9, 2013 |
|
- Johns Hopkins University
Baltimore, Maryland, United States
|
|
| 49 |
NCT00602771 |
Completed
Has Results |
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- (and 14 more...)
|
- Drug: tipifarnib
- Drug: etoposide
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
84 |
All |
70 Years and older (Older Adult) |
NCT00602771 |
NCI-2009-00278
CDR0000584212
J07109
8077
N01CM62204
P30CA006973
U01CA070095 |
|
January 2008 |
October 2011 |
October 2011 |
January 28, 2008 |
October 9, 2014 |
May 26, 2014 |
- Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States - Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - University of Michigan
Ann Arbor, Michigan, United States - (and 2 more...)
|
|
| 50 |
NCT01076569 |
Completed |
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia |
- Childhood Acute Basophilic Leukemia
- Childhood Acute Eosinophilic Leukemia
- Childhood Acute Erythroleukemia (M6)
- (and 9 more...)
|
- Other: laboratory biomarker analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Detailed molecular map of pediatric high-risk acute myeloid leukemia
- Mutations in identifying novel changes associated with pediatric AML
- Expression profile in identifying novel changes associated with pediatric AML
- (and 5 more...)
|
250 |
All |
up to 21 Years (Child, Adult) |
NCT01076569 |
AAML10B14
NCI-2011-02212
COG-AAML10B14
U10CA098543 |
|
March 2010 |
May 2016 |
May 2016 |
February 26, 2010 |
May 19, 2016 |
|
- Children's Oncology Group
Monrovia, California, United States
|
|
Create an RSS feed from your search for:
Download the search results for: